Comment on 'Impact of performance status on non-small cell lung cancer patients with a PD-L1 tumour proportion score ?50% treated with front-line pembrolizumab'

Kocak, Mehmet Zahid2024-02-232024-02-2320210284-186X1651-226Xhttps://doi.org/10.1080/0284186X.2021.1889028https://hdl.handle.net/20.500.12452/13042[Abstract Not Availabe]eninfo:eu-repo/semantics/openAccess[Keyword Not Available]Comment on 'Impact of performance status on non-small cell lung cancer patients with a PD-L1 tumour proportion score ?50% treated with front-line pembrolizumab'Editorial Material604564565336120572-s2.0-85101234364Q1WOS:000620048200001Q210.1080/0284186X.2021.1889028